作为COVID-19的治疗点ACE2,需要谨慎对待
1Department of Medical Technology, Heze Home Economics College, Shanxian, 274300, P. R. China. xx831006@163.com.
Archives of virology
|May 29, 2025
概括
抑制 ангиотензин转化酶2 (ACE2) 治疗SARS-CoV-2可能是有风险的,因为ACE2.
科学领域:
- 病毒学和分子生物学
- 病理生理学 病理生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- ангиотензин转化酶2 (ACE2) 对于SARS-CoV和SARS-CoV-2的进入至关重要.
- ACE2是COVID-19治疗的潜在治疗标.
- 了解ACE2在感染和治疗中的作用至关重要.
研究的目的:
- 挑战针对SARS-CoV和SARS-CoV-2感染的抗ACE2治疗策略的建议性.
- 审查ACE2和病毒进入机制的生理功能.
- 为了强调感染期间的病理性ACE2损伤和相关风险.
主要方法:
- 对ACE2生理作用的文献综述.
- 分析涉及ACE2的病毒进入机制2.
- 对针对ACE2的潜在治疗策略的评估2.
- 讨论与ACE2抑制相关的风险.
主要成果:
- 针对ACE2存在三种策略:阻断尖端蛋白相互作用,使用可溶性ACE2诱,并抑制ACE2活性.
- 抑制ACE2活性具有潜在的风险,并受到争议.
- 在SARS-CoV和SARS-CoV-2感染期间,ACE2的病理性损伤发生.
结论:
- 在COVID-19治疗中抑制ACE2活性的策略具有潜在的风险.
- 感染期间ACE2损害的潜在危险需要更多的注意.
- 由于潜在的副作用,研究人员应对抗ACE2治疗保持谨慎.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Atherosclerosis III: Management
42
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
42
Asthma: Pathogenesis and Management
623
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
623
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
913
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
913


